Abcam, ab237820, Anti-Chromogranin A antibody [CHGA/1731R] - BSA and Azide free

Size: 100µg
Rabbit Recombinant Monoclonal Chromogranin A antibody. Carrier free. Suitable for Protein Array, IHC-P and reacts with Recombinant full length protein - Human, Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human CHGA.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:CHGA/1731R,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-P, Protein ArraySee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Recombinant Full Length Protein corresponding to Human CHGA.P10645

Product details:
ab237820 is the carrier-free version of
ab237979
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A/G, Purification notes-Purified from bioreactor concentrate., Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Chromogranin A (CgA) sometimes called chromagranin A is a glycoprotein with a molecular weight of approximately 49–52 kDa. It is highly expressed in the secretory granules of neuroendocrine cells present in tissues such as the adrenal medulla pancreas and endocrine cells of the gastrointestinal tract. CgA identified as part of a family including chromogranin B and chromogranin C functions mechanically as a precursor to various bioactive peptides. This translates into its involvement in the storage and release of hormones and peptides within vesicles.
Biological function summary
Chromogranin A assists in the regulation of secretory pathways across multiple neuroendocrine systems. It plays a role in hormone storage conversion to active peptides and regulates the exocytosis of hormones. CgA acts within a complex contributing to secretory granule biogenesis and influencing intravesicular acidity. As a regulatory component the exact physiological roles are diverse impacting cardiovascular metabolic and immunological processes.
Pathways
Chromogranin A is involved in pathways such as the catecholamine synthesis and release pathway and the serotonergic pathway. Within these pathways it interacts with proteins like secretogranin II and parathyroid hormone (PTH). These interactions modulate neurotransmitter storage and secretion across various systems. CgA's bioactive peptides also contribute to modulating physiological processes like vasoconstriction and insulin regulation linking it closely with these signaling cascades.
Chromogranin A is a known marker for neuroendocrine tumors where its levels in blood may increase due to tumor activity. It links to diseases like pheochromocytoma and carcinoid tumors where improper regulation of CgA-associated pathways occurs. Additionally its connection to parathyroid disorders through the PTH pathway illustrates its broader implication in endocrine pathophysiology. CgA serves as an invaluable diagnostic and prognostic tool in these disease states and supports the development of targeted therapies.